Search Result

Results for "

MT

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (16) Adrenergic Receptor (2) Akt (4) Aldehyde Dehydrogenase (ALDH) (1) AMPK (1) Antibiotic (4) Apoptosis (11) Bacterial (10) Biochemical Assay Reagents (6) Btk (1) Carbonic Anhydrase (1) Caspase (2) CD19 (1) CD20 (1) CD3 (1) CD74 (1) Claudin (1) CXCR (3) Cytochrome P450 (2) Deubiquitinase (1) DNA Methyltransferase (1) Drug Derivative (2) Drug Isomer (1) Drug Metabolite (2) E3 Ligase Ligand-Linker Conjugates (2) EBV (1) Endogenous Metabolite (10) Epigenetic Reader Domain (1) ERK (2) Ferroptosis (3) Fluorescent Dye (2) Furin (1) Hippo (MST) (1) Histone Methyltransferase (1) HIV (31) HIV Integrase (4) HIV Protease (2) Influenza Virus (1) Interleukin Related (1) IRAK (1) Isotope-Labeled Compounds (5) JNK (2) Kinesin (1) Ligands for Target Protein for PROTAC (1) LPL Receptor (2) mAChR (1) Melanocortin Receptor (6) Melatonin Receptor (43) Microtubule/Tubulin (5) Mineralocorticoid Receptor (2) Mitochondrial Metabolism (1) Mitosis (1) MMP (5) mTOR (6) Myosin (5) NF-κB (1) Notch (1) Opioid Receptor (3) P2X Receptor (2) PAI-1 (1) Parasite (4) PDGFR (2) Peptide-Drug Conjugates (PDCs) (1) Phosphodiesterase (PDE) (1) Phosphoramidites (1) PKC (1) PPAR (2) Prostaglandin Receptor (2) PROTAC Linkers (1) PROTACs (3) PTEN (2) Reactive Oxygen Species (ROS) (4) Reference Standards (15) Reverse Transcriptase (6) SARS-CoV (3) Ser/Thr Protease (1) Sigma Receptor (1) Small Interfering RNA (siRNA) (42) Sodium Channel (2) STING (1) TGF-β Receptor (2) Transglutaminase (1) Trk Receptor (1) TRP Channel (3)
By Research Areas:	Cancer (60) Cardiovascular Disease (15) Endocrinology (14) Infection (45) Inflammation/Immunology (14) Metabolic Disease (14) Neurological Disease (59)
Click Chemistry:	Alkynes (1)
Oligonucleotides:	CpG ODNs (2) Rat Pre-designed siRNA Sets (7) Mouse Pre-designed siRNA Sets (8) Human Pre-designed siRNA Sets (27) Other Phosphoramidite (1) Phosphoramidites (1) siRNAs (42)

211

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P9963

Blinatumomab 2 Publications Verification bscCD19xCD3; AMG-103; MEDI-538; MT-103; BLINCYTO	CD19	Cancer
Blinatumomab (Anatumomab) is a bispecific monoclonal antibody with two binding sites, one for CD3E on T cells and one for CD19 on B cells. Blinatumomab can be used in research for acute lymphoblastic leukemia .

HY-P0267

Melanotan (MT)-II 1 Publications Verification	Melanocortin Receptor	Neurological Disease
Melanotan (MT)-II, a synthetic melanocortin receptor agonist, is an injectable peptide hormone used to promote tanning.

HY-109114

Dersimelagon MT-7117	Melanocortin Receptor	Metabolic Disease
Dersimelagon (MT-7117) is an orally active, selective melanocortin 1 receptor (MC1R) agonist with EC₅₀ values of 8.16, 3.91, 1.14 and 0.251 nM for human (h), cynomolgus monkey (cm), mouse (m) and rat (r) MC1R, respectively. Dersimelagon shows good affinity for hMC1R and hMC4R with K_i values of 2.26, 32.9 nM, respectively. Dersimelagon can be used for the research of skin pigmentation .

HY-101496

MT-DADMe-ImmA 4 Publications Verification MTDIA; Methylthio-DADMe-Immucillin A	Histone Methyltransferase	Cancer
MT-DADMe-ImmA is an inhibitor of human 5'-methylthioadenosine phosphorylase (MTAP) with a K_i of 90 pM.

HY-N2466

Melanotan I 1 Publications Verification MT-I; [Nle4,D-Phe7]-α-MSH	Melanocortin Receptor	Neurological Disease Cancer
Melanotan I is a potent non-selective melanocortin receptor (MCR) agonist. Melanotan I is a synthetic analogue of α-melanocyte stimulating hormone (α-MSH) that stimulates melanogenesis. Melanotan I can induce skin tanning by mimicking the actions of a-MSH on the melanocortin type 1 receptors (MC1R) of melanocytes. Melanotan I can be used for the research of sun-induced skin cancer, melanoma, inflammation and male erectile dysfunction .

HY-P99802

Pasotuxizumab 1 Publications Verification BAY 2010112; AMG 212; MT112	CD3	Cancer
Pasotuxizumab (BAY 2010112) is a PSMA and CD3 bispecific T-cell engager (BiTE). Pasotuxizumab binds to CD3 and PSMA with K_Ds of 9.4 nM and 47.0 nM for human CD3 and PSMA. Pasotuxizumab can be used for research of metastatic castration-resistant prostate cancer (mCRPC) .

HY-174406

MT-125	Myosin PDGFR Reactive Oxygen Species (ROS) Ferroptosis Akt mTOR ERK	Cancer
MT-125 is a specific and well-tolerated inhibitor of non-muscle myosin IIA (K_i,NMIIA = 2.7 μM) and IIB (EC₅₀ = 1.7 μM). MT-125 can pass through the blood-brain barrier. MT-125 induces ferroptosis and DNA damage by increasing the levels of reactive oxygen species (ROS) within tumor cells. MT-125 can enhance the PDGFR signaling pathway. MT-125 can be used for research on glioblastoma.

HY-16734A

Amiselimod hydrochloride MT-1303 hydrochloride	LPL Receptor	Cardiovascular Disease Inflammation/Immunology
Amiselimod (MT-1303) hydrochloride is converted to its active metabolite Amiselimod phosphate by sphingosine kinases in vivo. Amiselimod hydrochloride is an orally active and high selectivity sphingosine 1-phosphate receptor-1 (S1P1) agonist, designed to reduce the bradycardia effects associated with fingolimod and other S1P receptor modulators. Amiselimod hydrochloride inhibits chronic colitis via inhibiting infiltration of colitogenic Th1 and Th17 cells into the colon. Amiselimod hydrochloride inhibits lupus nephritis by reducing the infiltration of autoreactive T cells into the kidneys. Amiselimod hydrochloride is promising for research of autoimmune diseases .

HY-175188

MT-110 BPN-0027490	Myosin	Neurological Disease
MT-110 (BPN-0027490) is a non-muscle myosin NMIIB-selective inhibitor with high brain penetration and favorable safety profile. MT-110 specifically disrupts NMIIB-dependent actin dynamics in dendritic spines, while it exerts no significant adverse effects on cardiac myosin II and cardiac functions (such as cardiac output and heart rate) at tested concentrations. A single administration of MT-110 produces long-lasting (sustained for several weeks) blockade of methamphetamine motivation associated with environmental cues. MT-110 exhibits extremely high specificity, with no interference with cocaine motivation, hippocampus-dependent memory, fear memory, or locomotor and anxiety-like behaviors. MT-110 serves as a valuable tool compound for investigating the mechanisms of methamphetamine use disorder .

HY-175199

MT-228 BPN-0026709	Myosin	Neurological Disease
MT-228 (BPN-0026709) is a selective and blood-brain barrier permeable non-muscle myosin II inhibitor. MT-228 markedly improves tolerability by selectively targeting NMIIB (K_I = 1.5 μM) over CMII (K_I = 17 μM), and the sequence of SmMll MD is 83.6% identical to that of NMllB. MT-228 shows long-lasting efficacy in animal models of stimulant use disorder .

HY-147277

Lorundrostat MT-4129	Cytochrome P450	Cardiovascular Disease
Lorundrostat (MT-4129) is an orally active aldosterone synthase inhibitor. Lorundrostat can be used in studies of high blood pressure .

HY-128206

I3MT-3 5 Publications Verification HMPSNE	Hippo (MST)	Metabolic Disease
I3MT-3 (HMPSNE) is a potent, selective, and cell-membrane permeable inhibitor of 3-Mercaptopyruvate sulfurtransferase (3MST) (IC₅₀=2.7 μM). I3MT-3 is inactive for other H2S/sulfane sulfur-producing enzymes.?I3MT-3 targets a persulfurated cysteine residue located in the active site of 3MST .

HY-18973

Dp44mT 5 Publications Verification	Apoptosis Ferroptosis	Cancer
Dp44mT is an iron chelator with selective anticancer activity.

HY-122562

MT-802 4 Publications Verification	PROTACs Btk	Cancer
MT-802 is a BTK PROTAC degrader. MT-802 degrades wild-type BTK (DC₅₀ = 14.6 nM) and BTK mutants including E41K, C481S (DC₅₀ = 14.9 nM), C481R, C481Y, C481T, C481F, L528W, and inhibits their Y223 phosphorylation. BI-4732 can be used for the study of Ibrutinib (HY-10997)-resistant chronic lymphocytic leukemia (CLL). (Pink: BTK ligand (HY-150885), Blue: CRBN Ligand (HY-14658), Black: Linker (HY-141371), E3 ligase ligand-linker conjugate (HY-176340)) .

HY-174406A

MT-125 free base	Myosin PDGFR Reactive Oxygen Species (ROS) Ferroptosis Akt mTOR ERK	Inflammation/Immunology Cancer
MT-125 free base is a specific and well-tolerated inhibitor of non-muscle myosin IIA (K_i,NMIIA = 2.7 μM) and IIB (EC₅₀ = 1.7 μM). MT-125 free base can pass through the blood-brain barrier. MT-125 free base induces ferroptosis and DNA damage by increasing the levels of reactive oxygen species (ROS) within tumor cells. MT-125 free base can enhance the PDGFR signaling pathway. MT-125 free base can be used for research on glioblastoma.

HY-19469

Roluperidone 1 Publications Verification CYR-101; MIN-101; MT-210	5-HT Receptor Sigma Receptor	Neurological Disease
Roluperidone (CYR-101) is a novel cyclic amide derivative that has high equipotent affinities for 5-HT_2A and sigma-2 receptors (K_i of 7.53 nM and 8.19 nM for 5-HT_2A and sigma-2, respectively).

HY-109087

Elismetrep MT-8554	TRP Channel	Cardiovascular Disease Neurological Disease
Elismetrep (MT-8554) is a TRPM8 antagonist. Elismetrep reduces the frequency of vasomotor symptoms. Elismetrep can be used for study of pain .

HY-111976

MT1	Epigenetic Reader Domain	Cancer
MT1 is a bivalent chemical probe of BET bromodomains, with an IC₅₀ of 0.789 nM for BRD4(1) .

HY-128932

Cefminox sodium 1 Publications Verification MT-141	Antibiotic Bacterial PPAR Prostaglandin Receptor PTEN Akt mTOR	Infection Cardiovascular Disease Endocrinology
Cefminox sodium (MT-141) is a semisynthetic cephamycin, which exhibits antibacterial activity. Cefminox sodium is a broad-spectrum, bactericidal cephalosporin antibiotic. Cefminox sodium also acts as a dual agonist of prostacyclin receptor (IP) and PPARγ. Cefminox sodium upregulates cAMP production and PTEN expression and inhibits Akt/mTOR signaling. Cefminox sodium also prevents pulmonary arterial hypertension in rat model .

HY-W058849

MT 63-78	AMPK mTOR Apoptosis	Cancer
MT 63-78 is a specific and potent direct AMPK activator with an EC₅₀ of 25 μM. MT 63–78 also induces cell mitotic arrest and apoptosis. MT 63-78 blocks prostate cancer growth by inhibiting the lipogenesis and mTORC1 pathways. MT 63-78 has antitumor effects .

HY-P99959

Unasnemab MT-3921; rH116A3	TGF-β Receptor	Neurological Disease
Unasnemab (MT-3921) is a humanised IgG1 monoclonal antibody that binds to repulsive guidance molecule A (RGMa). Unasnemab improves locomotor function and promotes neuroregeneration. Unasnemab exerts ameliorative effects on hippocampal neurogenesis impairment and cognitive decline in db/db mice, Streptozotocin (STZ) (HY-13753)-induced type 1 diabetic and bilateral common carotid artery stenosis (BCAS)-induced mice. Unasnemab can be used for the research of spinal cord injury, diabetes-induced neurological impairments .

HY-128595

MT-4	Transglutaminase	Cancer
MT-4 is a derivative of a tissue transglutaminase (TG2) inhibitor. MT-4 targets the complex of TG2 and fibronectin (FN) (TG2/FN) and inhibits the adhesion of tumor cells to the matrix. MT-4 inhibits the adhesion of ovarian cancer (OC) cells to the peritoneum and increases the sensitivity of OC cells to paclitaxel.

HY-109002

Apararenone MT-3995	Mineralocorticoid Receptor	Cardiovascular Disease Metabolic Disease
Apararenone (MT-3995) is a novel non-steroidal mineralocorticoid receptor antagonists under development for the treatment of diabetic nephropathies and non-alcoholic steatohepatitis.

HY-147006

Zovodotin MT-VC-ZD02044	Mitosis	Cancer
MT-VC-ZD02044 is a cytotoxic and anti-mitotic agent .

HY-RS08743

MT2A Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
MT2A Human Pre-designed siRNA Set A contains three designed siRNAs for MT2A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MT2A Human Pre-designed siRNA Set A MT2A Human Pre-designed siRNA Set A

HY-N2466A

Melanotan I acetate 1 Publications Verification MT-I acetate; [Nle4,D-Phe7]-α-MSH acetate	Melanocortin Receptor	Cancer
Melanotan I acetate is a potent non-selective melanocortin receptor (MCR) agonist. Melanotan I acetate is a synthetic analogue of α-melanocyte stimulating hormone (α-MSH) that stimulates melanogenesis. Melanotan I acetate can induce skin tanning by mimicking the actions of a-MSH on the melanocortin type 1 receptors (MC1R) of melanocytes. Melanotan I acetate can be used for sunlight-induced skin cancers research .

HY-178431

MT-44	mTOR Apoptosis Reactive Oxygen Species (ROS) STING	Cancer
MT-44 is a highly selective and potent mTOR inhibitor with an IC₅₀ of 49.4 nM. MT-44 can inhibit cancer cells proliferation, migration and invasion. MT-44 can induce cells apoptosis and ROS production and cause G2/M phase arrest. MT-44 can activate the cGAS/STING pathway. MT-44 can be used for the research of cancer, such as triple-negative breast cancer .

HY-RS01052

AS3MT Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
AS3MT Human Pre-designed siRNA Set A contains three designed siRNAs for AS3MT gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

AS3MT Human Pre-designed siRNA Set A AS3MT Human Pre-designed siRNA Set A

HY-RS14893

TOP1MT Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
TOP1MT Human Pre-designed siRNA Set A contains three designed siRNAs for TOP1MT gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TOP1MT Human Pre-designed siRNA Set A TOP1MT Human Pre-designed siRNA Set A

HY-RS08757

MT-CO1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
MT-CO1 Human Pre-designed siRNA Set A contains three designed siRNAs for MT-CO1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MT-CO1 Human Pre-designed siRNA Set A MT-CO1 Human Pre-designed siRNA Set A

HY-RS16308

mt-Co1 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Infection Neurological Disease Cancer
mt-Co1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for mt-Co1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

mt-Co1 Mouse Pre-designed siRNA Set A mt-Co1 Mouse Pre-designed siRNA Set A

HY-141810

MT-134	Myosin	Others
MT-134 is a SkMII-specific inhibitor and has excellent exposure in muscles.

HY-155395

DDAN-MT	Fluorescent Dye	Infection
DDAN-MT is an enzymatic activated near-infrared fluorescent probe. DDAN-MT can be used for rapid, highly selective, and real-time monitoring of endogenous MtMET-AP1 activity in M. tuberculosis .

HY-180495

5-MeO-NBpBrT 5MT-NB4B	Drug Derivative Drug Isomer	Others
5-MeO-NBpBrT (Compound 2f) (5MT-NB4B) is a NBOMe derivative and 5MT-based N-(bromobenzyl) isomer .

HY-RS21159

mt-Nd5 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
mt-Nd5 Mouse Pre-designed siRNA Set A contains three designed siRNAs for mt-Nd5 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

mt-Nd5 Mouse Pre-designed siRNA Set A mt-Nd5 Mouse Pre-designed siRNA Set A

HY-16734

Amiselimod MT-1303	LPL Receptor	Cardiovascular Disease Inflammation/Immunology
Amiselimod (MT-1303) is converted to its active metabolite Amiselimod phosphate by sphingosine kinases in vivo. Amiselimod is an orally active and high selectivity sphingosine 1-phosphate receptor-1 (S1P1) agonist, designed to reduce the bradycardia effects associated with fingolimod and other S1P receptor modulators. Amiselimod inhibits chronic colitis via inhibiting infiltration of colitogenic Th1 and Th17 cells into the colon. Amiselimod inhibits lupus nephritis by reducing the infiltration of autoreactive T cells into the kidneys. Amiselimodis promising for research of autoimmune diseases .

HY-109114A

Dersimelagon phosphate MT-7117 phosphate	Melanocortin Receptor	Metabolic Disease
Dersimelagon phosphate is an orally active, selective melanocortin 1 receptor (MC1R) agonist with EC₅₀ values of 8.16, 3.91, 1.14 and 0.251 nM for human (h), cynomolgus monkey (cm), mouse (m) and rat (r) MC1R, respectively. Dersimelagon phosphate shows good affinity for hMC1R and hMC4R with K_i values of 2.26, 32.9 nM, respectively. Dersimelagon phosphate can be used for the research of skin pigmentation .

HY-136602

MT-21	Apoptosis JNK Caspase	Cancer
MT-21 is an Apoptosis inducer and adenine nucleotide translocase inhibitor. MT-21 induces Apoptosis by activating JNK via the Krs/MST protein. MT-21 activates caspase-3 via caspase-9. MT-21 induces the release of cytochrome c. MT-21 can be used in the research of tumors .

HY-122249

MT-7	Microtubule/Tubulin	Cancer
MT-7 is a potent mitotic inhibitor. MT-7 shows antiproliferative activity. MT-7 induces cell cycle arrest at G2/M phase. MT-7 induces specific, reversible mitotic arrest and inhibits the polymerization of cellular microtubules .

HY-162677

MT-1207	Adrenergic Receptor 5-HT Receptor	Cardiovascular Disease
MT-1207 is an orally active and selective adrenergic α₁ and 5-HT_2A receptor antagonist. MT-1207 shows IC₅₀<0.1 nM, 0.15 nM, 1.40 nM and 0.27 nM for α_1A, α_1B, α_1D and 5-HT_2A, respectively. MT-1207 achieves an effective blood pressure (BP) reduction in the 2K2C rat model without damaging renal function. MT-1207 is a potent multitarget inhibitor with the potential for vasodilatation research .

HY-122241

MT477	PKC	Cancer
MT477 is a potent protein kinase C (PKC) inhibitor. MT477 induces apoptosis and necrosis. MT477 decreases the protein expression of Ras-GTP, p-Erk1/2, p-Elk1. MT477 shows antitumor activity .

HY-128349

MT-3014	Phosphodiesterase (PDE)	Neurological Disease
MT-3014 is a potent, highly selective and brain-penetrated phosphodiesterase 10A (PDE 10A) inhibitor, with IC₅₀s of 0.062 nM and 0.09 nM for human PDE 10A and bovine PDE 10A, respectively .

HY-P991270

MT204	Interleukin Related	Inflammation/Immunology
MT204 is a humanized IgG1 antibody inhibitor targeting IL-2 of human and rhesus monkey origin. MT204 prevents soluble IL-2 from binding to intermediate-affinity IL-2 receptors and blocks CD25-bound IL-2 on high-affinity IL-2 receptors. MT204 has potently anti-proliferative activity with NKL cells and primary NK cells. MT204 has good tolerability and potent immunosuppressive activity in allogeneic skin graft model of rhesus monkey, promising for immunosuppressive and anti-proliferative therapy .

HY-107094

MT-7716 hydrochloride W-212393 hydrochloride	Opioid Receptor	Neurological Disease
MT-7716 hydrochloride (W-212393 hydrochloride) is a selective non-peptide nociceptin receptor (NOP) agonist and promising potential treatment drug for alcohol abuse and relapse prevention .

HY-168970

MT2A ligand 1	Ligands for Target Protein for PROTAC	Cancer
MT2A ligand 1 is a PROTAC target protein ligand (Ligand for Target Protein for PROTAC) targeting *MT2A*. MT2A ligand 1 can be used for synthesis AA-BR-157 (HY-168969) .

HY-107094A

MT-7716 free base W-212393	Opioid Receptor	Neurological Disease
MT-7716 free base (W-212393) is a selective non-peptide nociceptin receptor (NOP) agonist and promising potential treatment drug for alcohol abuse and relapse prevention .

HY-146300

Mt KARI-IN-4	Bacterial	Infection
Mt KARI-IN-4 (compound 5c) is a potent Mycobacterium tuberculosis ketol-acid reductoisomerase (Mtb KARI) inhibitor with a K_i value of 5.48 μM. Mt KARI-IN-4 has inhibitory activity against Mtb H37Rv (MIC = 0.78 μM) and low cytotoxicity (HEK IC₅₀ > 72 μg/mL) .

HY-146301

Mt KARI-IN-5	Bacterial	Infection
Mt KARI-IN-5 (compound 6c) is a potent Mycobacterium tuberculosis ketol-acid reductoisomerase (Mtb KARI) inhibitor with a K_i value of 4.72 μM. Mt KARI-IN-5 has inhibitory activity against Mtb H37Rv (MIC = 1.56 μM) and low cytotoxicity (HEK IC₅₀ > 64 μg/mL)

HY-146299

Mt KARI-IN-2	Bacterial	Infection
Mt KARI-IN-2 (compound 5b) is a potent Mycobacterium tuberculosis ketol-acid reductoisomerase (Mtb KARI) inhibitor with a K_i value of 2.02 μM. Mt KARI-IN-2 has inhibitory activity against Mtb H37Rv (MIC = 0.78 μM) and low cytotoxicity (HEK IC₅₀ > 86 μg/mL) .

HY-RS19565

Mt3 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Mt3 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Mt3 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Mt3 Mouse Pre-designed siRNA Set A Mt3 Mouse Pre-designed siRNA Set A

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-17038

Agomelatine Maximum Cited Publications 9 Publications Verification S-20098	Alkaloids Neurological Disease Classification of Application Fields Other Alkaloids Endogenous metabolite Disease Research Fields Source Classification	Melatonin Receptor 5-HT Receptor Endogenous Metabolite
Agomelatine (S-20098) is a specific agonist of *MT1* and *MT2* receptors with K_is of 0.1, 0.06, 0.12, and 0.27 nM for CHO-hMT1, HEK-hMT1, CHO-hMT2, and HEK-hMT2, respectively . Agomelatine is a selective 5-HT2C receptor antagonist with pK_is of 6.4 and 6.2 at native (porcine) and cloned, human 5-HT2C receptors, respectively .

HY-N0086R

N6-Methyladenosine (Standard) 1 Publications Verification 6-Methyladenosine (Standard); N-Methyladenosine (Standard)	Structural Classification Natural Products Microorganisms Endogenous metabolite Source Classification	Endogenous Metabolite Influenza Virus Reference Standards
N6-Methyladenosine (Standard) is the analytical standard of N6-Methyladenosine. This product is intended for research and analytical applications. N6-Methyladenosine is the most prevalent internal (non-cap) modification present in the messenger RNA (mRNA) of all higher eukaryotes. N6-Methyladenosine can modifies viral RNAs and has antiviral activities. In Vitro: N6-methyladenosine (m6A) is selectively recognized by the human YTH domain family 2 (YTHDF2) protein to regulate mRNA degradation. N6-methyladenosine (m6A), a prevalent internal modification in the messenger RNA of all eukaryotes, is post-transcriptionally installed by m6A methyltransferase (e.g., MT-A70) within the consensus sequence of G(m6A)C (70%) or A(m6A)C (30%). N6-methyladenosine (m6A)-containing RNAs are greatly enriched in the YTHDF-bound portion and diminished in the flow-through portion . N6-methyladenosine (m6A), the most abundant internal RNA modification, functions in diverse biological processes, including regulation of embryonic stem cell self-renewal and differentiation. N6-methyladenosine (m6A) is a large protein complex, consisting in part of methyltransferase-like 3 (METTL3) and methyltransferase-like 14 (METTL14) catalytic subunits .

HY-N16050

Ethyl salvianolate A Ethyl salvionolate A	Simple Phenylpropanols Labiatae Phenylpropanoids Plants Indigofera kirilowii Maxim. ex Palib Source Classification	HIV Reverse Transcriptase HIV Integrase HIV Protease
Ethyl salvianolate A (Ethyl salvionolate A) is an anti-HIV-1 compound that can be extracted from the roots of Salvia yunnanensis. Ethyl salvianolate A inhibits P24 antigen in HIV-1 infected MT-4 cell cultures (EC₅₀: 1.44 μg/mL). Ethyl salvianolate A inhibits HIV-1 replicative enzymes, with IC₅₀s of 56.38 μM (Reverse transcriptase), 12.03 μM (Protease), 14.54 μM (Integrase), respectively .

HY-17038A

Agomelatine hydrochloride Maximum Cited Publications 9 Publications Verification S-20098 hydrochloride	Alkaloids Neurological Disease Classification of Application Fields Other Alkaloids Endogenous metabolite Disease Research Fields Source Classification	Melatonin Receptor 5-HT Receptor Endogenous Metabolite
Agomelatine hydrochloride (S-20098 hydrochloride) is a specific agonist of *MT1* and *MT2* receptors with K_is of 0.1, 0.06, 0.12, and 0.27 nM for CHO-hMT1, HEK-hMT1, CHO-hMT2, and HEK-hMT2, respectively . Agomelatine hydrochloride is a selective 5-HT2C receptor antagonist with pK_is of 6.4 and 6.2 at native (porcine) and cloned, human 5-HT2C receptors, respectively .

HY-17038B

Agomelatine (L(+)-Tartaric acid) Maximum Cited Publications 9 Publications Verification S-20098 L(+)-Tartaric acid	Alkaloids Neurological Disease Classification of Application Fields Other Alkaloids Endogenous metabolite Disease Research Fields Source Classification	Melatonin Receptor 5-HT Receptor Endogenous Metabolite
Agomelatine L(+)-Tartaric acid (S-20098 L(+)-Tartaric acid) is a specific agonist of *MT1* and *MT2* receptors with K_is of 0.1, 0.06, 0.12, and 0.27 nM for CHO-hMT1, HEK-hMT1, CHO-hMT2, and HEK-hMT2, respectively . Agomelatine L(+)-Tartaric acid is a selective 5-HT2C receptor antagonist with pK_is of 6.4 and 6.2 at native (porcine) and cloned, human 5-HT2C receptors, respectively .

HY-17038R

Agomelatine (Standard) S-20098 (Standard)	Structural Classification Alkaloids Other Alkaloids Endogenous metabolite Source Classification	Reference Standards Melatonin Receptor 5-HT Receptor Endogenous Metabolite
Agomelatine (Standard) is the analytical standard of Agomelatine. This product is intended for research and analytical applications. Agomelatine (S-20098) is a specific agonist of *MT1* and *MT2* receptors with K_is of 0.1, 0.06, 0.12, and 0.27 nM for CHO-hMT1, HEK-hMT1, CHO-hMT2, and HEK-hMT2, respectively . Agomelatine is a selective 5-HT2C receptor antagonist with pK_is of 6.4 and 6.2 at native (porcine) and cloned, human 5-HT2C receptors, respectively .

HY-N12260

Benanomicin A	Quinones Microorganisms Anthraquinones Source Classification	HIV Bacterial
Benanomicin A is a microbial metabolite and can be isolated from Actinomycetes.Benanomicin has antifungal activitya and inhibits HIV-1 viral infection in MT-4 cells .

HY-137309

4-Deoxy-4α-phorbol	Terpenoids Euphorbia cooperi N. E. Br. ex A. Berger Diterpenoids Euphorbiaceae Plants Source Classification	HIV
4-Deoxy-4α-phorbol is a tetracyclic diterpene found in E. desmondi. It has been used in the semisynthesis of inhibitors of the HIV-1-induced cytopathic effect on MT-4 cells and 4α-phorbol esters .

HY-N11288

Methyl salvionolate A	Labiatae Phenols Polyphenols Plants Indigofera kirilowii Maxim. ex Palib Source Classification	HIV
Methyl salvionolate A is a potent inhibitor of HIV-1. Methyl salvionolate A inhibits P24 antigen in HIV-1 infected MT-4 cell with an EC₅₀ of 1.62 μg/ml. Methyl salvionolate A also inhibits HIV-1 reverse transcriptase, protease and integrase with IC₅₀s of 50.58, 10.73 and 7.58 μg/ml, respectively .

HY-17038AR

Agomelatine hydrochloride (Standard) S-20098 hydrochloride (Standard)	Structural Classification Alkaloids Other Alkaloids Endogenous metabolite Source Classification	Melatonin Receptor 5-HT Receptor Endogenous Metabolite Reference Standards
Agomelatine (hydrochloride) (Standard) is the analytical standard of Agomelatine (hydrochloride). This product is intended for research and analytical applications. Agomelatine hydrochloride (S-20098 hydrochloride) is a specific agonist of MT1 and MT2 receptors with Kis of 0.1, 0.06, 0.12, and 0.27 nM for CHO-hMT1, HEK-hMT1, CHO-hMT2, and HEK-hMT2, respectively . Agomelatine hydrochloride is a selective 5-HT2C receptor antagonist with pKis of 6.4 and 6.2 at native (porcine) and cloned, human 5-HT2C receptors, respectively .

HY-N9553

Alternarian acid	Structural Classification Monophenols Microorganisms Phenols Source Classification	Endogenous Metabolite
Alternarian acid is a polyketide compound found in the endophytic fungus Alternaria alternata MT-47, an endophytic fungus isolated from the medicinal plant of Huperzia serrata. Alternarian acid shows little inhibitory activity against thrombin-activated platelets, acetylcholinesterase, or butyrylcholinesterase .

Cat. No.	Product Name	Chemical Structure

HY-103005S

Ramelteon metabolite M-II-d3
Ramelteon metabolite M-II-d₃ is the deuterium labeled Ramelteon metabolite M-II. Ramelteon metabolite M-II is the major metabolite of Ramelteon, with IC₅₀s of 208 pM, 1470 pM for human melatonin receptors (MT1 or MT2). Ramelteon is a selective melatonin agonist .

HY-A0014S1

Ramelteon-d3

Ramelteon-d₃ (TAK-375-d₃) is a deuterium-labelled Ramelteon (HY-A0014). Ramelteon is a potent, highly selective, and orally active agonist of MT1/MT2 with K_i values of 14 and 112 pM, respectively. Ramelteon has the potential for the research of insomnia. Ramelteon consistently reduces sleep onset after long-term treatment, with no next-morning residual effects or rebound insomnia or withdrawal symptoms upon discontinuation.

HY-A0014S

Ramelteon-d5

Ramelteon-d₅ is deuterium labeled Ramelteon. Ramelteon is a potent, highly selective, and orally active agonist of MT1/MT2 with K_i values of 14 and 112 pM, respectively. Ramelteon has the potential for the research of insomnia. Ramelteon consistently reduces sleep onset after long-term treatment, with no next-morning residual effects or rebound insomnia or withdrawal symptoms upon discontinuation .

HY-17038S

Agomelatine-d6
Agomelatine-d₆ is deuterium labeled Agomelatine. Agomelatine is a specific agonist of MT1 and MT2 receptors .

HY-B0439S1

Sulfadoxine D3

Sulfadoxine-d₃ is a deuterium labeled Sulfadoxine (HY-B0439). Sulfadoxine is a sulfonamide that is used, usually in combination with Pyrimethamine(HY-18062), for multidrug-resistant Plasmodium falciparum and P. vivax inhibition. Unlike PYR, Sulfadoxine has no impact on HIV replication or MT-2 cell cycle progression. But also Sulfadoxine exhibits suppression on respiratory, and urinary tract infections .

HY-17038S2

Agomelatine-d3
Agomelatine-d₃ is the deuterium labeled Agomelatine. Agomelatine (S-20098) is a specific agonist of MT1 and MT2 receptors with K_is of 0.1, 0.06, 0.12, and 0.27 nM for CHO-hMT1, HEK-hMT1, CHO-hMT2, and HEK-hMT2, respectively . Agomelatine is a selective 5-HT2C receptor antagonist with pKis of 6.4 and 6.2 at native (porcine) and cloned, human 5-HT2C receptors, respectively .

HY-17038S1

Agomelatine-d4
Agomelatine-d₄ is the deuterium labeled Agomelatine. Agomelatine (S-20098) is a specific agonist of MT1 and MT2 receptors with K_is of 0.1, 0.06, 0.12, and 0.27 nM for CHO-hMT1, HEK-hMT1, CHO-hMT2, and HEK-hMT2, respectively . Agomelatine is a selective 5-HT2C receptor antagonist with pKis of 6.4 and 6.2 at native (porcine) and cloned, human 5-HT2C receptors, respectively .

HY-176436S

GW-117
GW-117 is a 5-HT2C receptor antagonist and a *melatonin (MT1/MT2) receptor* agonist. GW-117 shows antidepressant-like and anxiolytic-like effects .

HY-14803S

Tasimelteon-d5
Tasimelteon-d₅ is the deuterium labeled Tasimelteon. Tasimelteon (BMS-214778) is an orally active and selective dual melatonin receptor agonist (DMRA). Tasimelteon has 2.1-4.4 times greater affinity for the MT2 receptor than for the MT1 receptor. Tasimelteon is a circadian regulator and has the potential for Non-24-Hour Sleep-Wake Disorder (Non-24) .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks